Advertisement
U.S. markets close in 2 hours 15 minutes

TRACON Pharmaceuticals, Inc. (TCON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1751+0.0089 (+5.35%)
As of 01:36PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.1662
Open0.1744
Bid0.1751 x 800
Ask0.1790 x 1000
Day's Range0.1630 - 0.1790
52 Week Range0.1260 - 2.1900
Volume328,173
Avg. Volume1,845,424
Market Cap5.453M
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-0.4400
Earnings DateMar 06, 2024 - Mar 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TCON

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TRACON Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/20/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

    Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024 SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, t

  • InvestorPlace

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

    It’s time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth watching this morning! Moving stocks this morning are collaboration agreements, merger plans, earnings, public share offerings and more. Let’s get into that news down below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biggest Pre-Market Stock Movers: 10 Top Gainers Tracon Pharmaceuticals (NASDAQ:TCON) stock is rocketing more than 54% with heavy trading after announcing a product dev

  • GlobeNewswire

    TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment

    SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment. “We are excited